All In Biotech

Drug Trial Radar · NCT07443202

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

A Randomized, Vehicle-Controlled, Multicenter, Double-Masked, Parallel, Phase 2 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of Lotilaner Ophthalmic Gel in Participants With Ocular Rosacea (KORE)

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

155

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate lotilaner treatment in patients with ocular rosacea.

Conditions

  • Ocular Rosacea

Interventions

  • lotilanerDrug

    lotilaner

  • VehicleDrug

    Vehicle of lotilaner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse EventsTime frame: Week 16

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site

    Houston, Texas

  • Site

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.